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To characterize cancer risk in heterozygous p53 mutation carriers, we analyzed cancer incidence in 56 germline
p53 mutation carriers and 3,201 noncarriers from 107 kindreds ascertained through patients with childhood soft-
tissue sarcoma who were treated at the University of Texas M. D. Anderson Cancer Center. We systematically
followed members in these kindreds for cancer incidence for 120 years and evaluated their p53 gene status. We
found seven kindreds with germline p53 mutations that include both missense and truncation mutation types.
Kaplan-Meier analysis showed similar cancer risks between 21 missense and 35 truncation p53 mutation carriers
(log-rank ; ). We found a significantly higher cancer risk in female carriers than in male carriers2x p 0.04 Pp .84
(log-rank ; ), a difference not explained by an excess of sex-specific cancer. The calculated2x p 12.1 P ! .001
standardized incidence ratio (SIR) showed that mutation carriers had a risk for all types of cancer that was much
higher than that for the general population (SIR p 41.1; 95% confidence interval [CI] 29.9–55.0) whereas non-
carriers had a risk for all types of cancer that was similar to that in the general population (SIR p 0.9; 95% CI
0.8–1.0). The calculated SIRs showed a 1100-fold higher risk of sarcoma, female breast cancer, and hematologic
malignancies for the p53 mutation carriers and agreed with the findings of an earlier segregation analysis based
on the same cohort. These results quantitatively illustrated the spectrum of cancer risk in germline p53 mutation
carriers and will provide valuable reference for the evaluation and treatment of patients with cancer.
Introduction
The tumor-suppressor gene p53 (MIM 191170) plays
a central role in tumorigenesis (Levine 1997). Somatic
mutation of p53 has been found in 150% of human
cancers and is the most common genetic alteration in
human neoplasms (Hussain and Harris 1999; Martin
et al. 2002). Moreover, germline mutations of p53 have
been identified in 50%–70% of families with Li-Frau-
meni syndrome (LFS [MIM 151623]) (Frebourg et al.
1995; Varley et al. 1997; Bougeard et al. 2001). Germ-
line p53 mutations have been found in ∼1% of pa-
tients with early-onset breast cancer and in up to 9%
of patients with sarcoma in population-based studies
(Iavarone et al. 1992; Malkin et al. 1992; Kyritsis
et al. 1994; McIntyre et al. 1994; Diller et al. 1995;
Rapakko et al. 2001), and a substantial portion of
these carriers had a family history of cancer consistent
with LFS (Toguchida et al. 1992; Nichols et al. 2001).
Several other studies have showed that p53 mutation
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carriers had a remarkable risk of developing multiple
cancers (McIntyre et al. 1994; Saeki et al. 1997; Hisa-
da et al. 1998).
Most of these studies designed to identify germline p53
mutations, however, were deficient in the recruitment of
comparable control individuals and in long-term system-
atic follow-up and were therefore limited in their ability
to further characterize the cancer risks related to germline
p53 mutations. We have performed a long-term family
study that overcomes these limitations.We have collected
cancer-incidence data by following up, for 120 years, 159
extended families identified through 3-year survivors of
childhood soft-tissue sarcoma (STS) (Strong and Wil-
liams 1987). We have performed p53 mutation analy-
sis in 107 of these 159 kindreds, and we have identified
germline p53 mutations in 7 kindreds (Malkin et al.
1990; Law et al. 1991; Shete et al. 2002).
In the present study, we combined the cancer-incidence
data for relatives in these 107 kindreds to determine their
cancer risk by mutation type and by sex. We then com-
pared the type-specific cancer risk of p53 mutation car-
riers with that of noncarriers.
Subjects and Methods
Identification of Families and Cancer Incidence
The present study population was composed of blood
relatives in 159 extended families identified through 3-
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Table 1
Characteristics of Germline p53 Mutations in Seven Kindreds
with STS
Kindreda (Mutation Site)
Amino Acid
Change
No. of
Carriersb
No. of
Tumorsc
I (exon 8, codon 298) Glu-Stop 32 33
IId (exon 10, codon 365) His-Tyr 1 1
III (exon 5, codon 175) Arg-His 4 11
IV (exon 5, codon 184) Frameshift 4 10
V (exon 5, codon 133) Met-Thr 17 20
VIe (intron 9) … 2 2
VII (exon 7, codon 248) Arg-Trp 3 5
a All kindreds except kindred II had family histories of cancer that
are consistent with classic LFS.
b Confirmed carriers, identified either through direct mutation de-
tection or through inference based on family structure.
c Malignant tumors diagnosed in the carriers.
d De novo mutation.
e Splice mutation in intron 9.
Figure 1 Number of site-specific cancers for 56 germline p53
mutation carriers. Eleven carriers did not have cancer at the time of last
contact. A total of 67 malignant neoplasms were diagnosed for the 45
carriers (excluded probands). The “hematology” group comprises four
leukemia and twomultiple myeloma; the “gynecology” group comprises
four ovarian cancers, two prostate cancers, and one testicular cancer;
and the “others” group comprises three head and neck tumors, one
melanoma, and one thyroid cancer. G.I. p gastrointestinal.
year survivors of childhood STS who were diagnosed be-
tween 1944 and 1975 at the University of Texas M. D.
Anderson Cancer Center (Houston). Methods in the iden-
tification of families and the recording of cancer inci-
dence have been described elsewhere (Strong and Wil-
liams 1987; Bondy et al. 1992; Lustbader et al. 1992).
Here, we used medical records and death certificates to
verify the reported cancer or cancer-related heath con-
ditions. We defined case subjects with cancer as individ-
uals with any malignant tumor diagnosis except nonmel-
anoma skin cancer. The cancer incidence was truncated
at age 75 years, since the aim of the study was to identi-
fy early-onset cancer. As the result of these criteria, the
cancer risk of 107 probands and 3,257 relatives, to-
gether representing a total of 563 cancer diagnoses, was
investigated in the present study.
Subjects were classified as p53 mutation carriers if
they had a mutation or if both a parent and an offspring
were shown to be mutation carriers. Data for close rela-
tives of mutation carriers whose mutation status was un-
known—that is, those with a 50% probability of car-
rying the germline p53 mutation—were included only
in the calculation for standardized incidence ratio (SIR).
Subjects were classified as noncarriers if they were pro-
bands who did not have a mutation or were relatives
from p53 mutation–positive families who could be ex-
cluded from carrying a mutation.
Sample Collection and Mutation Testing
Peripheral-blood samples were collected from the pro-
bands and relatives after they signed informed consent
forms, and the present study has been approved by the
institutional review board of the University of Texas
M. D. Anderson Cancer Center. A total of 107 kindreds
were tested for p53 mutations: 92 had only the proband
tested, 3 had only affected close relatives tested, and 12
had both the proband and relatives tested. The remaining
kindreds could not be tested because of either deceased
probands whose relatives were not affected ( ) ornp 31
inadequate samples from probands ( ).np 21
Three of the seven mutations have been described else-
where (Malkin et al. 1990; Law et al. 1991). Mutations
reported here (in families I, II, III, and VI) were identified
using a combination of various assays: SSCP for exons
2–11, sequencing of exons 2–11, and the yeast func-
tional assay (Flaman et al. 1995; Evans et al. 1998).
Statistical Analyses
Among the mutation carriers, we tested for risk dif-
ferences according to both the type of p53 mutation
and the carriers’ sex, using the Kaplan-Meier product-
limit method. Differences in ages at cancer diagnosis be-
tween male and female carriers, as well as between those
with a truncation versus a missense mutation, were as-
sessed using the log-rank test, for which a P value !.05
was considered statistically significant. We further tested
for risk differences by using Cox’s proportional-hazards
regression model, to adjust for the potential confounding
factors of birth year and race. We used a robust variance
procedure to adjust for familial correlation in the propor-
tional-hazards model, which applied the approximate
jackknife estimate of variance to adjust for the correla-
tion between onset ages for family members (Lipsitz
and Parzen 1996). The time intervals in these regression
models were the time between birth and first-cancer
diagnosis, for those with cancer, and the time between
birth and last contact (December 31, 2001) or death
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Figure 2 Kaplan-Meier estimated cumulative incidence of all types of cancer—in 56 germline p53 mutation carriers (excluding probands)
identified in a cohort with childhood sarcoma. Ages shown are the time between birth and first-cancer diagnosis, for those with cancer, and
the time between birth and either last contact or death, for those without cancer. Among these 56 carriers, 21 carry missense mutations, and
35 carry truncation mutations.
(if before last contact), for those without cancer. All
statistical analyses were conducted using SAS/STAT,
version 6.12 (SAS Institute), and SPLUS, version 6
(Data Analysis Products Division).
Mutation carriers’ and noncarriers’ cancer risks were
further characterized with the SIR, which was calculated
using an updated Monson program called “Cohort Anal-
ysis for Genetic Epidemiology” (CAGE). The expected
number of cancer cases was calculated on the basis of
the study subjects’ birth year, age, and sex, to compare
with the cancer incidence reported by the Connecticut
Tumor Registry. The 95% CI was calculated from a
Poisson distribution. A 95% CI excluding 1 was con-
sidered as statistically significant. We compared the
SIR for the carriers with that for the noncarriers in the
study cohort, to minimize variations in the definition
of site-specific cancers, especially sarcoma. The SIRwas
calculated for a total of 18 groups of cancer diagnoses,
which included all cancer types for the 45 carriers who
developed cancer.
Results
Of the 107 kindreds, 7 (6.6%) harbored a germline p53
mutation (table 1). Six kindreds with p53 mutations had
family histories of cancer that are consistent with the clas-
sic LFS pattern. The H365Y mutation in kindred II was
considered to be de novo because there was no unusual
family history of cancer, but no samples from relatives
were available for mutation analysis. This mutation has
never been reported as a germline mutation but has been
reported once as a somatic mutation in a colorectal cancer
(Hayes et al. 1999; Hernandez-Boussard et al. 1999).
When the 7 probands with p53mutations were compared
with the 100 probands without p53 mutations, there was
no difference in the age at initial sarcoma diagnosis or in
survival time after STS diagnosis.
For the seven kindreds with mutations, a total of 63
carriers were identified either through direct mutation
detection or through inference based on family structure.
A total of 82 malignant tumors were confirmed in 52 of
63 mutation carriers, including probands. Of these tu-
mors, 52 (63%) were associated with classic LFS and
included sarcoma ( ), female breast cancer (np 28 np
), brain tumor ( ), and leukemia ( ). Of the17 np 3 np 4
remaining tumors, 16 are common adult-onset cancers,
such as lung ( ), colorectal ( ), and prostatenp 9 np 5
( ) cancers. Seventeen carriers eventually developednp 2
multiple primary neoplasms. The second malignancies
were diagnosed from 3mo to 33 years (median 9.3 years)
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Figure 3 Kaplan-Meier estimated cumulative incidence for all types of cancer—in 27 male and 29 female germline p53 mutation carriers.
Ages shown are the time between birth and first-cancer diagnosis, for those with cancer, and the time between birth and either last contact or
death, for those without cancer.
after the initial cancer diagnosis. By contrast, among 10
noncarriers who developed a second cancer, the second
cancers were diagnosed from 2 years to 34.5 years (me-
dian 5.8 years) after first-cancer diagnosis. Although no
noncarrier developed a third cancer, a total of seven car-
riers were diagnosed with a third cancer from 6 mo to
17.7 years after their second-cancer diagnosis. Among
these seven, three then developed a fourth cancer, and
one proband eventually developed a fifth cancer.
Of the 56 carriers who were not probands, 45 de-
veloped a total of 67 malignant tumors, with breast
cancer as the most common cancer, followed by STS
(fig. 1). Adulthood malignancies, such as lung and co-
lorectal cancer, were relatively common and occurred
in an even higher proportion than did osteosarcoma and
malignant brain tumor. Among the carriers, 12%, 35%,
52%, and 80% developed cancer by ages 20, 30, 40,
and 50 years, respectively, compared with the corre-
sponding cumulative risks of 0.7%, 1.0%, 2.2%, and
5.1% for the 3,201 noncarriers at the same ages. As
shown in figure 2, there was no difference in the cu-
mulative cancer risk for all types of cancer (log-rank
, with 1 df; ) between 21 missense2x p 0.04 Pp .84
and 35 truncation mutation carriers. Similar risk levels
were also observed for site-specific cancers between
these two groups of carriers (data not shown). For ex-
ample, a total of 13 carriers developed breast cancer
(one carrier had two primary breast cancers); of these
13 carriers, 4 (ages 25 to 46 years) were in the group
with missense mutations, and 9 (ages 25 to 52 years)
were in the group with truncation mutation (log-rank
, with 1 df; ). Among the 45 carriers2x p 0.18 Pp .66
who developed cancer, we observed a similar second-
cancer risk by mutation type, in 7 of the 18 with a
missense mutation and 6 of the 27 with a truncation
mutation (log-rank , with 1 df; ).2x p 1.94 Pp .16
The cancer risk for all carriers was also analyzed by
sex. At all ages, female carriers consistently had a higher
cancer risk (log-rank , with 1 df; ).2x p 12.1 P ! .001
Results of Cox’s proportional-hazards model showed
that female carriers had a 2.5-fold higher cancer risk
than did male carriers after adjustment for birth year,
race, and familial correlation of cancer, as shown in
figure 3. Female carriers had an earlier age at first-cancer
diagnosis than did male carriers (mean age at diagnosis,
29 vs. 40 years). By ages 20, 30, 40, and 50 years, the
female carriers had respective cumulative risks of 18%,
49%, 77%, and 93% for the development of cancer,
compared with respective cumulative risks of 10%,
21%, 33%, and 68% in the male carriers at the same
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Figure 4 Kaplan-Meier estimated cumulative incidence for all types of cancer—in 27 male and 12 female germline p53 mutation carriers.
Cases of breast, ovarian, and prostate cancer were excluded here. Ages shown are the time between birth and first-cancer diagnosis, for those
with cancer, and the time between birth and either last contact or death, for those without cancer.
ages. The difference in risk was not explained by the
high incidence of sex-specific cancer. Results of the Kap-
lan-Meier analysis showed a consistently higher cancer
risk in the female carriers (log-rank , with 12x p 3.7
df; ), even after the exclusion of cases of breast,Pp .05
ovarian, and prostate cancer (fig. 4).
In contrast to p53 mutation carriers, there was no
difference in the cancer risk for all types of cancer
between male and female noncarriers (1,625 males
and 1,576 females) (log-rank , with 1 df;2x p 0.62
). Also different from mutation carriers, thePp .43
risk for the 3,123 noncarriers after cases of breast,
ovarian, and prostate cancer were excluded was sig-
nificantly higher for men ( ) than for womennp 1,602
( ) (log-rank , with 1 df; ).2np 1,521 x p 8.5 P ! .003
This difference, however, was due to a higher cancer
incidence in the men after age 50 years. For the non-
carriers who developed cancer, the second-cancer risk
was the same for men and women; however, only 10
of the 324 noncarriers developed a second cancer.
The number of cancer cases in the present group of
3,201 noncarriers was no different from the number ex-
pected on the basis of cancer-incidence rates of the Con-
necticut Tumor Registry. However, in the group that we
studied, the noncarriers had a significantly lower risk for
colorectal cancer and malignancies of the buccal cavity
but a higher risk for STS. The higher STS risk in the
noncarriers may have been due to a difference in our
definition of STS, since we used the histological typing
(instead of site code only) to define STS and osteosar-
coma. The mutation carriers had a 41-fold higher risk
for all types of cancer relative to that for general popu-
lation and had a 1100-fold higher risk for LFS-compo-
nent cancers, such as sarcoma, female breast cancer, mul-
tiple myeloma, and ovarian cancer (table 2). The risk for
mutation carriers who had cancer to develop a second
cancer was also higher than that for the general popu-
lation ( ; 95% CI 7.1–19.6). We also deter-SIRp 12.3
mined the SIR for the 92 relatives in the p53 kindreds
who had a 50% probability of inheriting a germline p53
mutation, and we observed a 4.5-fold higher risk for all
types of cancer. This group of relatives had a significantly
higher risk for STS, female breast cancer, malignant brain
tumor, and leukemia than did the general population.
Discussion
The present study investigated the cancer risk in kindreds
ascertained on the basis of the presence of STS in their
probands, rather than on the basis of a history of excess
early-onset cancers, and thus is clearly different from
most reported studies of cancer-prone families. We iden-
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Table 2
SIRs for Relatives in 107 Kindreds Identified through 3-Year Survivors of Childhood STS, Grouped by Germline p53 Mutation Status
CANCER TYPE
ALL RELATIVES
( )Np 3,349
MUTATION CARRIERS
( )Np 56
RELATIVES WITH 50% RISK
( )Np 92
NONCARRIER
( )Np 3,201
N SIR (95% CI) N SIR (95% CI) N SIR (95% CI) N SIR (95% CI)
All cancera 398 1.0 (.9–1.1) 45 41.1 (29.9–55.0) 29 4.5 (2.9–6.4) 324 .9 (.8–1.0)
STS 21 6.8 (4.2–10.4) 8 302.8 (130.4–596.8) 4 69.7 (18.7–178.4) 9 3.0 (1.3–5.7)
Osteosarcoma 9 6.0 (2.7–11.5) 5 289.0 (93.1–674.4) 0 … 4 2.7 (.7–7.1)
Female breast 66 1.0 (.8–1.3) 13 105.1 (55.9–179.8) 5 5.7 (1.8–13.3) 48 .7 (.5–1.0)
Brain 20 2.3 (1.4–3.6) 3 45.0 (9.0–131.5) 7 49.4 (19.8–101.7) 10 1.2 (.5–2.2)
Leukemia 25 2.0 (1.3–3.0) 4 47.3 (12.7–121.1) 3 12.0 (2.4–35.0) 18 1.5 (.9–2.4)
Multiple myeloma 10 2.5 (1.2–4.6) 2 171.6 (19.2–619.6) 0 … 8 2.0 (.8–4.0)
Ovarian 12 1.1 (.5–1.9) 4 120.5 (32.4–308.5) 1 5.4 (.0–30.0) 7 .6 (.2–1.3)
Lung 63 .9 (.7–1.2) 8 38.5 (16.6–76.0) 3 3.0 (.6–8.8) 52 .8 (.6–1.0)
Prostate 25 .8 (.5–1.2) 2 52.2 (5.8–188.7) 1 1.8 (.0–10.4) 22 .8 (.5–1.2)
Esophagus 2 .3 (.04–1.1) 1 46.6 (.6–259.6) 0 … 1 .1 (.0–.9)
Pancreas 12 1.0 (.5–1.8) 1 30.5 (.4–170.1) 2 9.2 (1.0–33.3) 9 .8 (.4–1.5)
Liver 5 .8(.2–1.9) 1 60.7 (.7–337.9) 0 … 4 .6 (.1–1.7)
Colon 27 .6 (.4–.8) 2 18.1 (2.0–65.6) 1 1.2 (.0–6.7) 24 .5 (.3–.8)
Rectal 11 .4 (.2–.8) 3 45.5 (9.1–133.1) 0 … 8 .3 (.1–.7)
Buccal cavity 4 .2 (.1–.6) 1 12.8 (.1–71.2) 0 … 3 .1 (.04–.5)
Melanoma 15 1.3 (.7–2.1) 1 11.0 (.1–61.6) 1 7.9 (.1–44.4) 13 1.1 (.6–1.9)
Testicular 4 1.4 (.3–3.7) 1 23.2 (.3–129.1) 0 … 3 1.1 (.2–3.3)
a All types of cancer except nonmelanoma skin cancer.
tified germline p53 mutations in 6.6% of the kindreds
that we studied, a percentage that is similar to the 4.1%
identified in 196 case subjects with sarcoma and the 9%
in 33 case subjects with rhabdomyosarcoma (Toguchida
et al. 1992; Diller et al. 1995). We characterized the
cancer risks of p53 mutation carriers and comparable
noncarriers who had been systematically followed for
120 years. The noncarriers had a cancer risk that was
almost identical to that for the general population. In
the p53 mutation carriers, we observed several charac-
teristics that were consistent with previously reported
findings: LFS-component cancers represented the largest
proportion of cancer incidence, and breast cancers rep-
resented the largest number of tumors diagnosed (Klei-
hues et al. 1997). We also observed significantly earlier
ages at onset of gastrointestinal and lung cancers for the
mutation carriers, supporting a previous suggestion to
include these cancer types as possible LFS components
(Varley et al. 1997). However, in contrast with a previous
report (Birch et al. 2001), there were only a few rare
cancer types in our carriers: no adrenocortical carcinoma
or Wilms tumor and only one phyllodes tumor.
We also observed a 12-fold higher second-cancer risk
for the carriers, which was similar to the risk reported
for the 24 families with LFS that had had their first
cancer diagnosed between ages 20 and 44 years (Hisada
et al. 1998). Although it appeared to take longer for
the carriers to develop a second cancer than for the
noncarriers, this difference was mainly due to the car-
riers’ earlier age at first-cancer diagnosis.
p53 is unique among tumor-suppressor genes: most
p53 mutations are missense mutations, whereas trun-
cation mutations are more common for other tumor-
suppressor genes (Hernandez-Boussard et al. 1999; Hus-
sain and Harris 1999; Guimaraes and Hainaut 2002).
Several laboratory and animal studies have suggested
that some p53 mutants have dominant-negative activ-
ity over the wild-type p53 or gain new functions (Ditt-
mer et al. 1993; Hsiao et al. 1994; Gualberto et al.
1998; Blagosklonny 2000; Hixon et al. 2000; Sigal and
Rotter 2000; van Oijen and Slootweg 2000). The novel
functions of mutant p53 may be caused by inhibition
of wild-type p53 through hetero-oligomerization or by
acquiring abilities to bind new DNA sequences or new
protein partners (Roemer 1999; Cadwell and Zambetti
2001). The hypothesis of mutant p53’s gain of func-
tion has also been suggested on the basis of a study of
families with LFS (Birch et al. 1998). The study by Birch
et al. (1998) reported a significantly higher cancer in-
cidence and earlier age at cancer diagnosis in families
with LFS that carry missense mutations at the DNA
binding domain of p53 than in families that carry pro-
tein-inactivation mutations. In addition, a significantly
higher risk for breast and CNS cancers was observed
in families with mutations at the DNA binding domain.
The present study did not show a higher cancer inci-
dence or earlier onset in p53 mutation carriers who had
missense mutations at the central core domain or p53
than in those who had truncation mutations. In several
studies, two of the kindreds studied that carried missense
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mutations (R175H and R248W) have been shown to
have gain-of-function and/or dominant-negative activi-
ties (Wang et al. 1998; Di Como et al. 1999; Roemer
1999); however, there was no difference in cancer risk
between these two groups of mutation carriers. We used
only data for confirmedmutation carriers, instead of data
for all the relatives in the p53 mutation–positive kin-
dreds. These two groups of carriers had similar distri-
butions of sex and birth years and thus represented a
unique cohort for testing the hypothesis of mutant p53’s
gain of function. The differences in data source, the p53
mutation sites, and strategies for family recruitment may
all contribute to the difference of findings between the
present study and previous studies.
We observed nearly equal numbers of male and fe-
male p53mutation carriers, which is a finding consistent
with the results of a meta-analysis (Kleihues et al. 1997).
We observed cancer risk to be significantly higher in
female p53 carriers than in male carriers, which is a
finding that had not, to our knowledge, been described
previously. The latter finding is consistent with a report
of different risk for the development of tumors between
male and female mutant p53 mice: the incidence of os-
teosarcoma was observed to be consistently higher in
female mice than in male mice, regardless of genetic
backgrounds (Donehower et al. 1995). There are also
several anecdotal reports supporting that male p53 mu-
tation carriers may have a lower risk for cancer than
female carriers. One of the three subjects with germline
p53 mutations who were studied by Toguchida et al.
(1992) had an unaffected father in his mid-50s. In a
kindred that carried the R290H mutation, the father of
a 9-year-old girl who had a brain tumor and the father
of the girl’s first cousin, who died of rhabdomyosar-
coma, were unaffected (Quesnel et al. 1999). In a germ-
line p53 mutation–positive family reported by Saeki et
al. (1997), two of the four male carriers in the probands’
generation were unaffected, whereas both female car-
riers, including the proband, were affected. Grayson et
al. (1994) have reported an unaffected 38-year-old fa-
ther of a p53 mutation carrier who had adrenal cortical
carcinoma. Sun et al. (1996) have reported a p53 mu-
tation–positive family with late-onset breast cancer and
have noted unaffected male relatives—but, again, no fe-
males—in their 50s and 70s. In the present study cohort,
all female carriers developed cancer by age 55 years,
whereas six male carriers were still unaffected at age 50
years and two of them were unaffected at age 60 years.
It is not clear yet what is the mechanism for the sex
difference in cancer risk. The significantly earlier age at
cancer onset in the female carriers was not due simply
to the incidence of female breast cancer; we also ob-
served an increased risk for brain and lung cancer in
women. The large difference between men and women
in age at cancer diagnosis and the large number of child-
hood and adolescent cancer cases among the mutation
carriers lessened the possibility that the sex-related dif-
ferences could be explained by the fact that women seek
medical care more frequently than men. It is tempting
to speculate that sex hormones may contribute to this
observation; however, we could not investigate this in
detail, because all female mutation carriers developed
cancer by age 55 years. It is expected that future study,
to evaluate cancer risk in a larger group of mutation
carriers, will further characterize the sex difference and
may aid in the generation of biological mechanisms that
lead to the difference.
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